

AMENDMENTS TO THE CLAIMS

1. (Original) A method of treating a patient suffering from Mild Cognitive Impairment, comprising administering to the patient an effective amount of (+)-isopropyl 2- methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate.

2. (Original) A method of treating a patient suffering from neuronal damage as a result of CNS hypoxia comprising administering to the patient an effective amount of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5 -dicarboxylate.

3. (Previously Presented) A method according to claim 2, wherein said neuronal damage is the result of Coronary Artery Bypass Grafting (CABG).

4. (Currently Amended) A method according to claim 2, wherein said patent is treated for memory impairment and/or cognitive impairment due to such neuronal damage[[],].

5. (Previously Presented) A method of treating a patient suffering from memory impairment and/or cognitive impairment due to schizophrenia, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, and other neurological conditions, comprising administering to the patient an effective amount of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate.

6. (Cancelled)

7. (Cancelled)

8. (Original) A method of treating a patient suffering from suffering from conditions of memory and/or cognition impairment due to disease states selected from attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD), comprising administering to the patient an effective amount of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl) 1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate.

9. (Original) A method of treating a patient suffering from suffering from tinnitus and/or other symptoms of cerebral insufficiency, comprising administering to the patient an effective amount of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate.

10. (Currently Amended) A method according claim [[1]] 9, further comprising administering to said patient one or more further pharmaceutical agents ~~for the treatment of cognitive impairment and/or memory loss~~, wherein said one or more further pharmaceutical agents are selected from nicotinic α -7 agonists, PDE4 inhibitors, calcium channel blockers, muscarinic m1 and m2 modulators, adenosine receptor modulators, ampdines, NMDA-R modulators, mGluR modulators, dopamine modulators, serotonin modulators, and cannabinoid modulators.

11. (Previously Presented) A method according to claim 10, wherein said one or more further pharmaceutical agents are selected from amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine, nitrendipine, nisoldipine, and memantine.

12. (Currently Amended) A method ~~of treating a patient suffering from memory and/or cognitive impairment associated with schizophrenia~~ according to claim ~~[[5]]~~ 9, further comprising administering to said patient an effective amount of one or more further pharmaceutical agents selected from Clozaril, Zyprexa, Risperidone, and Seroquel.

13. (Currently Amended) A method ~~of treating a patient suffering from memory and/or cognitive impairment associated with Huntington's disease~~ according to claim ~~[[5]]~~ 9, further comprising administering to said patient an effective amount of one or more further pharmaceutical agents selected from Arnitriptyline, Imipramine, Despiramine, Nortriptyline, Paroxetine, Fluoxetine, Sertraline, Tetrabenazine, Haloperidol, Chlorpromazine, Thioridazine, Sulpride, Quetiapine, Clozapine, and Risperidone.

14. (Currently Amended) A method ~~of treating a patient suffering from memory and/or cognitive impairment associated with Attention Deficit Hyperactivity Disorder (ADHD)~~ according to claim ~~[[8]]~~ 9, further comprising administering to said patient an effective amount of one or more further pharmaceutical agents selected from Ritalin, Dexedrine, Dextrostat, Cylert, and Adderall.

15. (Cancelled)

16. (Currently Amended) A method according to claim 9, further comprising administering of treating a patient suffering from memory and/or cognitive impairment associated with Alzheimer's disease comprising administering to the patient an effective amount of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate and an effective amount of one or more further pharmaceutical agents selected from Akatinol, Neotropin, Eldepryl, Estrogen, and Clioquinol.

17. (Currently Amended) A method according to claim 9, further comprising administering of treating a patient suffering from memory and/or cognitive impairment associated with Parkinson's disease comprising administering to the patient an effective amount of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate and an effective amount of one or more further pharmaceutical agents selected from Levodopa, Parlodel, Permax, Mirapex, Tasmar, Comtan, Kemadrin, Artane, and Cogentin.

18. (Currently Amended) A method according to claim 9, further comprising administering of treating a patient suffering from memory and/or cognitive impairment associated with depression comprising administering to the patient an effective amount of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate and an effective amount of one or more further pharmaceutical agents selected from Prozac, Zoloft, Paxil, Reboxetine, Wellbutrin, Olanzapine, Fluoxetine, Elavil, Tofranil, Pamelor, Nardil, Parnate,

Desyrel, Effexor, Desyrel, Vivactil, Sinequan, Parnate, Zyprexa, Tryptanol, Serzone, Risperidal, Haldol, Faverin, Seroxat, Remeron, or Nortrilene.

19. (Currently Amended) A method according to claim 9, further comprising administering of treating a patient suffering from memory and/or cognitive impairment associated with dementia comprising administering to the patient an effective amount of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate and an effective amount of one or more further pharmaceutical agents selected from Thioridazine, Haloperidol, and Risperidone.

20. (Cancelled)

21. (Currently Amended): A method according to claim 9, further comprising administering of treating a patient suffering from memory and/or cognitive impairment associated with bipolar disorder comprising administering to the patient an effective amount of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate and an effective amount of one or more additional pharmaceutical agents selected from Lithium, Depakote, and Zyprexa.

22. (Currently Amended) A method according to claim [[1]] 9, wherein said patient is human.

23. (Previously Presented) A pharmaceutical composition comprising (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate and one or more additional pharmaceutical agents selected from Lithium, Depakote, and Zyprexa.

24. (Currently Amended) A pharmaceutical composition according to claim [[24]] 23, further comprising one or more further pharmaceutical agents selected from nicotinic α -7 agonists, PDE4 inhibitors, calcium channel blockers, muscarinic m1 and m2 modulators, adenosine receptor modulators, arnpakines, NMDA-R modulators, mGluR modulators, dopamine modulators, serotonin modulators, and cannabinoid modulators.